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BACKGROUND: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal
squamous cell carcinoma (ESCC) patients.
METHODS: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage
(C/D ratio) as CCND1 copy number. This study was divided into three steps: (1) Determination of a cutoff value for the C/D ratio in
test scale; (2) Comparison of the C/D ratio in between plasma samples and cancer tissues in ESCC patients showing high plasma
C/D ratio; (3) Validation study of the clinical application of the plasma C/D ratio as a diagnostic and prognostic marker, by comparing
with clinicopathologic factors in 96 ESCC patients.
RESULTS: The plasma C/D ratio was significantly higher in the ESCC group than the controls (P¼0.0134). A high plasma C/D ratio
reflected the tumour C/D ratio, and significantly correlated with a poorer prognosis (P¼0.0186). Moreover, the high C/D ratio was
found to be an independent prognostic factor on multivariate analysis (P¼0.0266; hazard ratio 5.988).
CONCLUSION: Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC
patients.
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Oesophageal cancer occurs worldwide with a variable geographic
distribution, and ranks eighth in order of occurrence and is the
sixth leading cause of cancer mortality (Enzinger and Mayer,
2003). Although there are two different kinds of histologic types of
oesophageal cancer, squamous cell carcinoma (ESCC) accounts for
B90% of all oesophageal cancer diagnosed in Asian countries
(Hiyama et al, 2007). In spite of the recent advances in diagnostic
techniques and perioperative management, patients with ESCC still
show extremely poor survival rates even after extended surgery.
Several recent studies have elucidated that certain molecules,
such as p53, cyclin D1 (CCND1) and FAS, have important roles in
tumourigenesis and the development of the ESCC (Hollstein et al,
1990; Ade ´laide et al, 1995; Shinozaki et al, 1996; Gratas et al, 1998).
However, few molecules have been applied in clinical setting as
therapeutic and/or diagnostic biomarkers. Therefore, the signifi-
cance of detecting a novel biomarker using reasonable molecules
should be emphasised.
Among several molecules, gene amplification of CCND1 mapped
to the 11q13 region, which is a key regulator of the G1 phase of the
cell cycle, has been defined as one of the most common genetic
aberrations in ESCC, and has been shown to correlate with
advanced stage and poor prognosis (Jiang et al, 1992; Kyomoto
et al, 1997). In contrast, recent reports have shown that tumour
released circulating DNA and RNA in plasma–serum samples were
useful for detecting the tumour-specific abnormalities and
monitoring disease status in cancers (Sozzi et al, 2003; Kimura
et al, 2006; Skvortsova et al, 2006; Diehl et al, 2008; Schwarzenbach
et al, 2009).
Therefore, we hypothesised that the genome status of CCND1
in primary oesophageal cancer could be predictable by a less
invasive, blood-based test, which enable to evaluate primary
tumour dynamics and predict prognosis and associated clinico-
pathological factors. To circumvent the influences of plasma DNA
quantity and numerical chromosomal aberrations, we particularly
calculated the ratio of the dosage of CCND1 to that of the reference
gene, dopamine receptor D2 (DRD2) gene mapped to 11q22-23, as
an indicator of the CCND1 copy number (CCND1/DRD2: C/D
ratio) (Kyomoto et al, 1997).
In this study, we showed whether the plasma C/D ratio is useful to
predict tumour CCND1 amplification in preliminary 40 ESCC
patients, and examined the diagnostic value of the C/D ratio to
detect cancers by comparing findings in ESCC patients and healthy
volunteer controls. In addition, we validate the prognostic value of the
C/D ratio by analysing the relationship between the plasma results
and clinicopathological factors in 96 consecutive ESCC patients.
MATERIALS AND METHODS
Patients and samples
Between October 2007 and April 2009, recent 40 preoperative
plasma samples were collected from consecutive patients with
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sESCC, who underwent R0 (no residual tumour after surgery) or
R1 (microscopic residual tumour after surgery) esophagectomy at
the Kyoto Prefectural University of Medicine, as well as from
19 healthy volunteers. After determination of the cutoff value for
the plasma C/D ratio (see the section ‘Quantitative analysis for
CCND1 using real-time polymerase chain reaction’ described
below), we divided the 40 patients into two groups, 19 patients
with a high plasma C/D ratio and 21 with a low plasma C/D ratio.
Paraffin-embedded oesophageal tumour tissues and adjacent
normal oesophageal tissues were collected from the same 19
patients showing the high plasma C/D ratio. To obtain additional
evidence that the tumour-derived circulating DNA reflect the
plasma C/D ratio, the postoperative plasma samples (20–51 days
after operation) were also collected from eight patients in the high
plasma C/D ratio group, who underwent R0 esophagectomy.
Plasma samples were collected from another 56 consecutive
ESCC patients and another 21 healthy volunteers for large-scale
validation assays. In total, plasma sample were collected from
40 healthy volunteers and 96 consecutive ESCC patients who
underwent curative surgery (R0 or R1) between April 2005 and
April 2009.
Resected cancer specimens were fixed in buffered formalin and
embedded in paraffin for routine pathological examination.
Pathological classification of the tumour was determined accord-
ing to the UICC classification (Sobin and Fleming, 2002).
Preparation and DNA isolation of plasma and tissues
samples
After obtaining informed consent, 7ml of peripheral blood was
obtained from each patient before any surgery, and from healthy
volunteer controls. Immediately after collection, the blood samples
were subjected to the isolation of cell-free nucleic acids by the
three spin protocol (1500r.p.m. for 30min, 3000r.p.m. for 5min,
4500r.p.m. for 5min) to prevent cross contamination from cellular
nucleic acid (Tomita et al, 2007). After centrifugation, the plasma
sample was stored at  801C until further processing. Cell-free
genomic DNA was isolated from 400ml of the serum sample using
the QIAamp blood mini kit (Qiagen, Hilden, Germany). The final
elution was performed using a 100ml of the AE buffer of the
QIAamp blood mini kit.
Paraffin-embedded tissues were sectioned at 5mm thickness
after undergoing routine histologic examination. Genomic DNA of
cancerous and adjacent noncancerous oesophageal tissues were
extracted from the two slices 5mm thick using DEXPAT (TaKaRa,
Kyoto, Japan) according to the manufacturer’s protocols.
Quantitative analysis for CCND1 using real-time PCR
We selected the DRD2 gene as a reference gene, because the DRD2
is located on the same chromosome as CCND1, and DRD2
amplification and overexpression in ESCC have never reported in
any gene database, such as GenBank, DDBJ and EMBL. Therefore,
the CCND1/DRD2 ratio would reflect the CCND1 copy number
without influence of absolute DNA concentration and aneuploidy
of chromosome 11.
The serum dosage of CCND1 and DRD2 were quantified by
DNA-based real-time PCR using Applied Biosystems 7300 Real-
Time PCR system (Applied Biosystems, Foster City, CA, USA). The
PCR mixture was a final volume of 20ml containing 10ml TaqMan
Universal PCR Master Mix (Applied Biosystems), 1ml TaqMan
Gene Expression Assays and 9ml each DNA samples. TaqMan
Gene Expression Assays for CCND1 (Hs03772544_cn) and DRD2
(Hs05266854_cn) were purchased from Applied Biosystems. All
PCR reactions were performed with one cycle of 951C for 10min,
followed by PCR amplification with 40 cycles of 951C for 15s and
601C for 60s.
The CCND1 copy number of DNA samples was determined by
the ratio of the CCND1 dosage to the DRD2 dosage (C/D ratio),
using the comparative threshold cycle method.
Statistical analysis
The difference in the plasma C/D ratio between the ESCC
and healthy volunteer control groups was assessed using the
Mann–Whitney U-test, and that between preoperative and
postoperative findings was assessed using Wilcoxon t-test.
w
2 test, Fisher’s exact probability test was used to evaluate the
correlations between results of the plasma C/D ratio and
clinicopathological factors. P-values o0.05 were considered
statistically significant. Moreover, overall survival rate was
calculated using Kaplan–Meier method, and the significance of
differences was determined by log-rank test. Multivariate stepwise
Cox regression model was performed to identify significant
contributors that were associated independently with death on
univariate analysis; multivariate risk ratios are presented with
95% confidence intervals.
RESULTS
Study design to develop a novel genomic biomarker of the
plasma
The study design is summarised in Figure 1A. This study was
divided into three steps: (1) Determination of a cutoff value of the
C/D ratio by comparing results of both plasma from 40 ESCC
patients and 19 healthy volunteers; (2) Evaluation whether plasma
C/D ratio could monitor tumour dynamics; (3) Validation study
for clinical application as a diagnostic and prognostic marker,
using the plasma C/D ratio, by comparing the plasma results with
clinicopathologic factors in 96 ESCC patients.
Test scale for detection cutoff value of plasma
CCND1/DRD2 ratio
Plasma C/D ratio of 40 ESCC patients and 19 healthy volunteer
controls was examined by real-time PCR to determine the cutoff
value. Figure 1B shows the distribution of the plasma C/D ratio in
ESCC patients and in the control groups. The plasma C/D ratio was
significantly higher in the ESCC patients group than control group
(median: 1.23 (range 0.19–7.32) vs median: 1.05 (range 0.39–1.79),
P¼0.0134). Consequently, we determined a cutoff value of 1.33 for
the plasma C/D ratio based on the mean value þ s.d. in healthy
volunteer controls to distinguish the high C/D ratio patients from
those with low ratio patients. As a result, 19 patients were
categorised into high plasma C/D ratio group, whereas 21 patients
in low plasma C/D ratio group.
Evaluation whether plasma CCND1/DRD2 ratio could
monitor tumour dynamics
We analysed the C/D ratio of oesophageal cancer and adjacent
normal oesophageal tissues in 19 ESCC patients showing a high
plasma C/D ratio. The higher C/D ratio of oesophageal tumour
compared with that of normal tissues was found in 14 of the 19
patients (74%) (Table 1), while a higher C/D ratio of oesophageal
tumour was found in only 6 of the 21 ESCC patients showing a low
plasma C/D ratio (Supplementary Table 1). These findings
indicated that the high plasma C/D ratio reflects the amplification
in tumour. Moreover, we examined the CCND1 assay in post-
operative plasma of eight patients showing high plasma C/D
ratio in preoperative plasma. The C/D ratio reduced significantly
in the postoperative plasma samples (P¼0.0357; Figure 1C).
In one patient, the re-elevation of plasma C/D ratio was found at
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s16 month after surgery, who developed recurrence without
elevation of conventional serum tumour marker such as squamous
cell carcinoma antigen (SCC) (Figure 1D).
Large scale for validation in the clinical application as a
diagnostic and prognostic biomarker
In total, 96 consecutive patients were included in this study;
the mean age of patients was 64.2 years (range: 44–82), the
male–female ratio was 3.4:1, and 9 with TNM stage 0, 23 with
stage I, 35 with stage II, 21 with stage III and 8 with stage IV. The
mean follow-up period was 13.8 months (range: 0–40). Figure 2
shows the receiver-operating characteristic curves for plasma C/D
ratio analysis, and the area under the curve was 0.728. Sensitivity
was 43.7% (42 out of 96) and specificity was 87.5% (35 out of 40)
(Supplementary Figure 1).
Correlations between plasma C/D ratio and clinicopathological
factors in 96 ESCC patients are summarised in Table 2. The
At diagnosis
(operation) 































































































Mean ± s.d : 0.957 ± 0.371
3. Large-scale for validation in the clinical application of
the plasma CCND1/DRD2 ratio 
Plasma samples from consecutive 96 ESCC patients
were analysed
Comparison of the CCND1/DRD2 ratio between
plasma samples and tumour tissue
The receiver-operating characteristic (ROC) curve for
the plasma CCND1/DRD2 ratio analysis
Evaluation of associated clinicopathological factors
and prognostic value
Comparison of plasma CCND1/DRD2 ratio between
pre-operation and post-operation in patients with ESCC
1. Test-scale to determine a cut-off value of the plasma
CCND1/DRD2 ratio
Examination of plasma CCND1/DRD2 ratio in 40 ESCC
patients and 19 healthy volunteers




































Figure 1 Study design and initial results to develop a novel genomic biomarker of the plasma. (A) Strategy to identify novel plasma potential biomarker in
ESCC. (B) Comparison of plasma CCND1/DRD2 (C/D) ratio in 40 ESCC patients and 19 healthy volunteers by real-time PCR. The plasma CCND1/DRD2
ratio was significantly higher in the ESCC group (median: 1.24, range: 0.19–6.56) than in the control group (median: 1.05, range: 0.39–1.79).
(C) Comparison of plasma CCND1/DRD2 ratio between pre- and postoperative plasma. The plasma CCND1/DRD2 ratio was also examined
postoperatively in eight patients showing a high plasma CCND1/DRD2 ratio in preoperative plasma, and the value was significantly reduced in postoperative
plasma (P¼0.0357, Wilcoxon t-test). (D) Changes of the plasma CCND1/DRD2 ratio and SCC antigen in one patient who developed recurrences. The
top and bottom graphs represent the value of the plasma CCND1/DRD2 ratio and SCC antigen level, respectively. The dotted lines represent the upper
limit of each marker: 1.33 for plasma CCND1/DRD2 ratio and 1.5ngml
–1for SCC antigen. The patients underwent esophagectomy, however, radiologic
examination showed multiple recurrences, lymph nodes and lungs, 12 months postoperatively. The plasma CCND1/DRD2 ratio re-elevated at the time of
diagnosis of recurrences.






19 14 (74%) 5 (26%)
Abbreviations: CCND1¼cyclin D1; DRD2¼dopamine receptor D2.
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spatients showing high plasma C/D ratio tended to have lymph
node metastasis although the difference was not significant. There
was no significant correlation between the plasma C/D ratio and
other clinicopathological factors in this study.
We additionally validated the plasma C/D ratio as a prognostic
value in 96 ESCC patients. Patients in the high plasma C/D ratio
group showed significantly poorer survival than those in the low
ratio group (3-year survival rates: 59.4 vs 86.1%, P¼0.0186)
(Figure 3). Univariate analysis showed that the T-stage was also a
significant prognostic factor. Both the plasma C/D ratio
(P¼0.0266 hazard ratio 5.988 (range: 1.232–29.411)) and T-stage
were found to be independent prognostic factors on multivariate
analysis (Table 3).
DISCUSSION
A noninvasive assay using circulating nucleic acids opens up a new
and interesting field in the screening and monitoring of cancer
patients. Several investigators have recently reported that the
detections of tumour-derived circulating DNA and RNA would be
promising diagnostic and prognostic tools in clinical practise
(Johnson and Lo, 2002; Fleischhacker and Schmidt, 2007). A
majority of these approaches, however, require complicated
processing including certain modifications. Furthermore, strict
handling is required in cases of mRNA assays.
However, gene amplification is one of the most frequent
genomic aberrations involved in the pathogenesis of various
cancers. Especially in ESCC, oncogenes, such as SMYD2 (1q32.3-
q41), EGFR (7p12), MYC (8q24.21), CCND1 (11q13), cIAP1
(11q22) and ERBB2 (17q21.1), have already been identified as
major amplification targets associated with development, progres-
sion and metastasis of aggressive disease (Lu et al, 1988; Imoto
et al, 2001; Jain et al, 2007; Komatsu et al, 2009; Sato-Kuwabara
et al, 2009). Among them, CCND1 is the gene most frequently
amplified (22–65%) with high copy numbers, and also associated
with a poorer survival outcome in ESCC patients (Lam, 2000).
These findings prompted us to detect the CCND1 amplification in
plasma samples of ESCC patients, as well as to examine the clinical
usefulness of the noninvasive assay as a possible biomarker.
To circumvent the aneuploidy of chromosomes, we first deve-
loped real-time quantitative PCR with a reference gene mapped to
the same chromosome, and subsequently showed that the ratio,
CCND1 (11q13) / DRD2 (11q22-23), in plasma DNA is a valuable
diagnostic tool for detecting cancers, monitoring therapeutic
effects and predicting both clinicopathological factors and post-
operative prognosis of ESCC patients. We analysed whether the
plasma C/D ratio could monitor tumour dynamics by two different
analyses in advance. One is the comparison between the plasma
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Figure 2 The receiver-operating characteristic (ROC) curves for the
plasma CCND1/DRD2 ratio analysis in 96 ESCC patients and 40 healthy
volunteers. The area under the curve (AUC) was 0.728 in 96 ESCC
patients vs 40 healthy volunteers.
Table 2 Correlation between clinicopathological factors and the plasma
CCND1/DRD2 ratio in consecutive 96 patients with ESCC
Plasma CCND1 amplification value
Variable n Low High P-value
b
Total 96 54 (56.3%) 42 (43.7%)
Sex
Male 74 44 (59.5%) 30 (40.5%) 0.2450
Female 22 10 (45.5%) 12 (54.5%)
Age
o65 42 24 (57.1%) 18 (42.9%) 0.8764
65% 54 30 (55.6%) 24 (44.4%)
Lymphatic invasion
Negative 67 40 (59.7%) 27 (40.3%) 0.3001
Positive 29 14 (48.3%) 15 (51.7%)
Venous invasion
Negative 58 30 (51.7%) 28 (48.3%) 0.2694
Positive 38 24 (63.2%) 14 (36.8%)
T stage
a
T0/1/2 57 33 (57.9%) 24 (42.1%) 0.6945
T3/4 39 21 (53.8%) 18 (46.2%)
N stage
a
N0 54 35 (64.8%) 19 (35.2%) 0.0550
N1 42 19 (45.2%) 23 (54.8%)
Stage
a
0–II 67 39 (58.2%) 28 (41.8%) 0.5564
III–IV 29 15 (51.7%) 14 (48.3%)
Recurrence
Negative 72 44 (61.1%) 28 (38.9%) 0.0963
Positive 24 10 (41.7%) 14 (58.3%)
Abbreviations: CCND1¼cyclin D1; ESCC¼oesophageal squamous cell carcinoma;
DRD2¼dopamine receptor D2.
aTNM classification.
bP-values are from w
2 or





































0 1400 1200 1000 800 600 400 200
Figure 3 Comparison survival curves according to plasma CCND1/
DRD2 (C/D) ratio in 96 consecutive patients with ESCC. Patients with a
high plasma C/D ratio (1.33p) showed significantly poorer survival than
those with low ratio (P¼0.0186).
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stumour C/D ratio was high compared with that of adjacent normal
tissue in most patients with a high plasma C/D ratio. The reasons
for the discrepancies in some patients remain to be identified;
however, one possible explanation for this finding is the hetero-
geneity of the primary tumours. Another analysis involves
comparison of the plasma C/D ratio in paired plasma obtained
before and after surgery. As a result, the plasma C/D ratio was
significantly reduced postoperatively in patients who underwent
R0 esophagectomy, suggesting that tumour-derived circulating
DNA reflect the plasma C/D ratio.
The plasma copy number assay presented in this study has
several possibilities for clinical application. First is the screening
method in the high-risk group of patients. This assay could detect
an elevated C/D ratio regardless of disease stage (detection rate;
stage 0–II vs III–IV: 42.8 vs 48.2%) and tumour depth (T0–T2 vs
T3–4: 42.1 vs 46.2%). These findings suggest that the tumour could
release a significant amount of genomic DNA into systemic
circulation even at an early stage, and also copy number gains
(10–100 copy) derived from CCND1 amplification of each cancer
cell chromosome is drastic. This phenomenon was reported in
other studies as well as our previous studies showing that the
concentration of plasma DNA in cancer patients was significantly
higher than that in controls, regardless of tumour stage (Sai et al,
2007; Tomita et al, 2007). Therefore, circulating DNA in peripheral
blood may be an early event in the carcinogenesis of solid cancers,
and allow the monitoring tumour dynamics as well as prediction of
both associated clinicopathological factors and the prognosis at an
early stage.
The second possibility is the clinical application as a marker to
monitor therapeutic efficacy (Figure 1C) and recurrence as a
complement to conventional serum tumour markers, such as SCC
and CEA. In this study, the plasma C/D ratio decreased to the
normal range after surgery and increased again at recurrence
without any change in conventional serum tumour markers
(Figure 1D). In addition, the most interesting finding to be
emphasised was that this assay could also be useful for predicting
patients with poor prognoses. This is the first plasma–serum copy
number study to predict the prognosis in cancer patients, although
the copy number of the amplified genes in plasma or serum has
been evaluated in some previous studies (Chiang et al, 1999; Gotoh
et al, 2005; Park et al, 2009).
Other benefits of this assay include the savings of time and effort
compared with those required for other plasma–serum assays.
TaqMan real-time PCR assay allows us to easily evaluate the copy
numbers of plasma amplified genes in a couple of hours.
Previously, we reported that methylation-specific PCR (MSP)
assays using circulating DNA could be combined to serve as a
tumour marker in gastric cancer (Ichikawa et al, 2004; Koike et al,
2004). We also showed that the quantification of circulating mRNA
such as hTERT and MUC1 using RT–PCR would be useful for
the early detection of primary and recurrent gastric cancers
(Tani et al, 2007). However, these assays are time-consuming,
and required strict conditions and handlings. Besides, the
detection rates of MSP and quantitative mRNA assays are relatively
low (15–30%). Our present plasma copy number assay is more
suitable for clinical application from the perspective technical
simplicity, rapidity and reliability.
We present here a framework to assess tumour characteristics
by noninvasive plasma assay. Recent advances in molecular
technologies have allowed the analysis of numerous gene and
chromosomal aberrations within the entire genome. In the near
future, we could design a ‘tailor-made biomarker’ assay, based on
exhaustive evaluation of genes amplifications in primary tumours.
This strategy is currently under evaluation.
In conclusion, this study clearly showed that plasma-based
CCND1 copy number provides a valuable biomarker for monitor-
ing treatment efficacy and predicting both the associated clinical
factors and prognosis of ESCC. This technology could facilitate
clinical decision making and be applicable to tailor-made medicine
for each individual.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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